CN114728001A - 使用bcn057和bcn512的治疗方法 - Google Patents

使用bcn057和bcn512的治疗方法 Download PDF

Info

Publication number
CN114728001A
CN114728001A CN202080074897.6A CN202080074897A CN114728001A CN 114728001 A CN114728001 A CN 114728001A CN 202080074897 A CN202080074897 A CN 202080074897A CN 114728001 A CN114728001 A CN 114728001A
Authority
CN
China
Prior art keywords
fibrosis
formula
cancer
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080074897.6A
Other languages
English (en)
Chinese (zh)
Inventor
安德鲁·诺里斯
苏迪普·查克拉博蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bisian Bioscience Co ltd
Original Assignee
Bisian Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bisian Bioscience Co ltd filed Critical Bisian Bioscience Co ltd
Publication of CN114728001A publication Critical patent/CN114728001A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080074897.6A 2019-08-24 2020-08-24 使用bcn057和bcn512的治疗方法 Pending CN114728001A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891338P 2019-08-24 2019-08-24
US62/891,338 2019-08-24
PCT/US2020/047692 WO2021041347A1 (en) 2019-08-24 2020-08-24 Methods of treatment using bcn057 and bcn512

Publications (1)

Publication Number Publication Date
CN114728001A true CN114728001A (zh) 2022-07-08

Family

ID=74647168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074897.6A Pending CN114728001A (zh) 2019-08-24 2020-08-24 使用bcn057和bcn512的治疗方法

Country Status (6)

Country Link
US (2) US11358964B2 (enExample)
EP (1) EP4017493A4 (enExample)
JP (3) JP2022545287A (enExample)
CN (1) CN114728001A (enExample)
AU (2) AU2020337892B2 (enExample)
WO (1) WO2021041347A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118541368A (zh) * 2021-09-03 2024-08-23 比西恩生物科学有限责任公司 使用bcn057、bcn077及类似物的治疗方法
US20240122916A1 (en) * 2022-10-08 2024-04-18 Radmit, Inc. Effect of YEL002 on Conditions and Diseases
US20240325375A1 (en) * 2023-04-01 2024-10-03 Radmit, Inc. Effect of YEL002 on Psychological and Psychiatric Factors in Health and Disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104233A1 (en) * 2016-10-16 2018-04-19 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
US20190046524A1 (en) * 2017-08-08 2019-02-14 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using compound 512

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
AU2018346962A1 (en) * 2017-10-12 2020-05-28 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104233A1 (en) * 2016-10-16 2018-04-19 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
US20190046524A1 (en) * 2017-08-08 2019-02-14 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using compound 512

Also Published As

Publication number Publication date
AU2020337892A1 (en) 2022-05-19
US11358964B2 (en) 2022-06-14
AU2025267506A1 (en) 2025-12-11
JP2025032222A (ja) 2025-03-11
AU2020337892B2 (en) 2025-08-14
WO2021041347A1 (en) 2021-03-04
US20230035771A1 (en) 2023-02-02
EP4017493A4 (en) 2023-08-23
JP2026127687A (ja) 2026-08-06
US20210053968A1 (en) 2021-02-25
EP4017493A1 (en) 2022-06-29
US12435081B2 (en) 2025-10-07
JP2022545287A (ja) 2022-10-26

Similar Documents

Publication Publication Date Title
US12435081B2 (en) Methods of treatment using BCN057 and BCN512
JP6627835B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
KR20160113287A (ko) 단백질 응집 저해제로서의 헤테로아릴 아미드
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN121695155A (zh) 减少与甲状腺相关的副作用的方法
US20220160701A1 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
BRPI0712938A2 (pt) mÉtodo para modular excrescÊncia de neurito pelo uso de um antagonista de receptor de galanina-3
JP2025081626A (ja) ペンタミジンの類似体及びその使用
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
KR20160005356A (ko) 방사선완화 약제학적 제형
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
US11364231B2 (en) Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using YEL002/BCN057
BRPI0718904A2 (pt) Pirrol[1,2-a] imidazolodiona efetiva no tratamento de neurotoxicidade induzida por agentes quimioterapêuticos
US20240376098A1 (en) Methods of treatment using bcn057, bcn077 and analogs
US11534437B2 (en) Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512
WO2024213057A1 (zh) Lsd1抑制剂与药物联用治疗癌症的用途
CN120731078A (zh) 治疗或预防败血症或与败血症相关的病情的化合物
KR20220093208A (ko) 프로스타글란딘 아날로그 및 이들의 용도
JPWO2019146670A1 (ja) 光応答性Ｓｍｏｏｔｈｅｎｅｄリガンド
WO2017156222A1 (en) Radiomitigating compounds, compositions and methods related thereto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination